We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Next Gen Digital Colposcope with AI Capabilities Redefines Cervical Cancer Screening

By HospiMedica International staff writers
Posted on 10 May 2023
Print article
Image: The EVAPro next gen digital colposcope is redefining cervical examination (Photo courtesy of MobileODT)
Image: The EVAPro next gen digital colposcope is redefining cervical examination (Photo courtesy of MobileODT)

Cervical cancer ranks as the 4th most common cancer among women globally. With over 300,000 women succumbing to cervical cancer annually, prompt follow-up and receiving immediate results at the point of care could be transformative. Now, an AI-powered digital mobile colposcope offers a screening alternative to the existing standard of care for cervical cancer, boasting significantly enhanced accuracy and speed – delivering results in under a minute.

MobileODT’s (Tel Aviv, Israel) EVAPro introduces the latest digital advancement in cervical cancer screening, improving the patient-physician experience. The next-gen EVAPro digital colposcope is lightweight and portable, offering exceptional image quality and advanced software capabilities. This unique combination enables physicians to document and monitor the entire treatment process and store it on the cloud. EVAPro-produced images are self-illuminating, enabling clearer image capture. Image assessment features a green filter to evaluate abnormal vessels and other landmarks or lesions. With autofocus, each image is assessed for multiple factors: cervix presence, illumination, cervix position, and image focus. Image-guided technology and ML allow image quality assessment, notifying the clinician that the image is suitable for visual inspection or colposcopic evaluation.

EVAPro employs AI and Machine Learning (ML) for large-scale cervical cancer screening. VisualCheck, an AI-based computer-aided diagnostic tool, operates on the EVAPro digital colposcope and evaluates the risk of dysplasia at the point of care. VisualCheck compares images captured during an exam with thousands of prior exams annotated by leading experts and histology results, predicting their classification. The algorithm is designed to recognize and identify CIN2+ based on data from 17 different countries. Clinical evaluation of VisualCheck reveals consistent agreement rates between VisualCheck scores and expert panels across three separate locations. VisualCheck is the only computer-aided diagnostic tool that evaluates the likelihood of cervical dysplasia, offering hope to women without direct access to specialists.

In addition to hosting the VisualCheck algorithm, the EVAPro digital colposcope provides various advanced features to support colposcopy. Fully portable and Wi-Fi enabled, EVAPro allows for instant consultation, either within the hospital or globally, while captured images can be uploaded and shared remotely. These images can be annotated for precise consultation by specialists in other locations. Consulting physicians can view the biopsy's real-time location and timing. For practitioners in remote or resource-limited areas, this can mean the difference between rapid diagnosis and treatment or a lengthy delay between testing and treatment. Furthermore, the system can be easily integrated into medical records, offering a visual record of an exam and a historical record useful for clinicians seeing the same patient in the future.

Related Links:
MobileODT 

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Multilevel Self-Loading Stretcher
CARRERA XL

Print article

Channels

Surgical Techniques

view channel
Image: LUMISIGHT and Lumicell DVS offer 84% diagnostic accuracy in detecting residual cancer (Photo courtesy of Lumicell)

Cutting-Edge Imaging Platform Detects Residual Breast Cancer Missed During Lumpectomy Surgery

Breast cancer is becoming increasingly common, with statistics indicating that 1 in 8 women will develop the disease in their lifetime. Lumpectomy remains the predominant surgical intervention for treating... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.